Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 14 years
- Director since
- 2023
14 years of board service in total across 4 boards, counting each seat separately. Longest: Madrigal Pharmaceuticals Inc., 3 years.
Madrigal Pharmaceuticals Inc.
Director
Protara Therapeutics Inc.
Director
Kodiak Sciences Inc
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Madrigal Pharmaceuticals Inc. June 20, 202593.6%
-
Kiniksa Pharmaceuticals International plc June 3, 202597.6%
-
Kodiak Sciences Inc June 2, 202577.6%
-
Protara Therapeutics Inc. June 7, 202498.6%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 1, 2026 | Kiniksa Pharmaceuticals International plc | Option exercise | +403 | — | — |
| Jun 17, 2026 | Madrigal Pharmaceuticals Inc. | Grant or award | +454 | — | — |
| May 29, 2026 | Kiniksa Pharmaceuticals International plc | Option exercise | +2,799 | — | — |
| May 22, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −40 | $506.68 | $20,267 |
| May 22, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −320 | $508.24 | $162,637 |
| May 22, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −151 | $510.36 | $77,064 |
| May 22, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −610 | $511.40 | $311,954 |
| May 22, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −439 | $512.50 | $224,988 |
| May 22, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −40 | $512.97 | $20,519 |
| May 22, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −343 | $514.67 | $176,532 |
| May 22, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −657 | $515.92 | $338,959 |
| May 22, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −723 | $516.87 | $373,697 |
| May 22, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −1,497 | $517.59 | $774,832 |
| May 22, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −782 | $518.76 | $405,670 |
| May 22, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −80 | $519.98 | $41,598 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.